Why the study?
Does dronedarone reduce hospitalization due to cardiovascular events or death in patients with atrial fibrillation?
Population
patients with atrial fibrillation
Authors
Loading...
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The ATHENA trial shows that dronedarone, a new antiarryhtmic drug similar to amiodarone but with different effects on individual ion channels, reduced the risk of death or hospitalisation for cardiovascular reasons by 36% when compared with placebo. This was in patients without severe heart failure (NYHA class IV) but with paroxysmal or persistent atrial fibrillation or flutter with additional risk factor for death.”
Supports dronedarone consideration in AF; confirms benefit on CV hospitalization or death.
Does dronedarone reduce hospitalization due to cardiovascular events or death in patients with atrial fibrillation?
Dronedarone reduces the composite of cardiovascular hospitalization or death in patients with atrial fibrillation.
Hohnloser et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: